Cell therapy (CAR-T) · Kills target cells, directed at CD7 · developed by Beam Therapeutics
BEAM-201 is an allogeneic, off-the-shelf CAR-T cell preparation made from donor T lymphocytes that have been base-edited and transduced with a lentiviral vector to express an anti-CD7 chimeric antigen receptor. The cells bind CD7-expressing tumor cells and kill them. It is being studied in T-cell lymphoblastic leukemia and lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05885464 | Phase 1/2 | Lymphoblastic Lymphoma | Active not recruiting | BEAM |
| NCT06934382 | Phase 1 | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Recruiting | BEAM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lymphoblastic LeukemiaLymphoblastic LymphomaT-Cell Acute Lymphoblastic Leukemia/LymphomaT-Cell Lymphoblastic Leukemia/Lymphoma
Updated Oct 11, 2026. Something wrong or missing? Report it on the BEAM page.
See BEAM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BEAM catalysts and pipeline →